[1]
S. SHAFI and G. Yattoo, “Spectrum, Clinico-pathological Profile of Non-Alcoholic Fatty Liver Disease and its Treatment Response with 48week Therapy of Saroglitazar”, jms, vol. 24, no. Suppl 1, May 2021.